Family Offices Betting On Biofoundries

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Family Offices Betting On Biofoundries

Listen for free

View show details

We explore how ultra-high-net-worth family offices are moving beyond traditional biotech equity into direct ownership of biofoundries—the automated labs that serve as the hardware for synthetic biology. With companies like Ginkgo Bioworks raising capital and the broader sector facing valuation pressure, we examine why families are structuring bespoke partnerships with these platforms rather than just buying stock. We look at the specific economics of lab access versus IP licensing, the operational risks of biological manufacturing, and the long-term play in programmable cells. This is a deep dive into the infrastructure layer of the next industrial revolution. #FamilyOffice #SyntheticBiology #Biofoundry #GinkgoBioworks #PrivateEquity #BiotechInvesting #VentureCapital #IndustrialBiotech #WealthManagement #AlternativeAssets #LabAutomation #Genomics #DeepTech #SustainableMaterials #FexingoBusiness #BusinessPodcast #FinanceStrategy #Innovation Keep every episode free: buymeacoffee.com/fexingo

No reviews yet